180 related articles for article (PubMed ID: 19734846)
41. Type X collagen expression and hypertrophic differentiation in chondrogenic neoplasias.
Aigner T; Frischholz S; Dertinger S; Beier F; Girkontaité I; von der Mark K
Histochem Cell Biol; 1997 Jun; 107(6):435-40. PubMed ID: 9243276
[TBL] [Abstract][Full Text] [Related]
42. FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb).
Al-Hassi HO; Ali NM; Cooke H; De Silva S; Brini AT; Babu P; Sumathi V; Morris MR; Niada S
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397231
[No Abstract] [Full Text] [Related]
43. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
44. Diagnosis and prognosis of chondrosarcoma of bone.
Rozeman LB; Hogendoorn PC; Bovée JV
Expert Rev Mol Diagn; 2002 Sep; 2(5):461-72. PubMed ID: 12271817
[TBL] [Abstract][Full Text] [Related]
45. The molecular pathogenesis of dedifferentiated chondrosarcoma.
Sakamoto A
Indian J Orthop; 2014 May; 48(3):262-5. PubMed ID: 24932031
[TBL] [Abstract][Full Text] [Related]
46. Dedifferentiated chondrosarcoma with muscle and cytokeratin differentiation in the anaplastic component.
Dervan PA; O'Loughlin J; Hurson BJ
Histopathology; 1988 May; 12(5):517-26. PubMed ID: 2456261
[TBL] [Abstract][Full Text] [Related]
47. Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes.
Bovée JV; Sciot R; Dal Cin P; Debiec-Rychter M; van Zelderen-Bhola SL; Cornelisse CJ; Hogendoorn PC
Diagn Mol Pathol; 2001 Dec; 10(4):228-35. PubMed ID: 11763313
[TBL] [Abstract][Full Text] [Related]
48. [Clinicopathologic diagnosis of de-differentiated chondrosarcoma].
Huang J; Zhang HZ; Zheng L; Zhou J; Jiang ZM
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):820-3. PubMed ID: 20193457
[TBL] [Abstract][Full Text] [Related]
49. H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis.
Sakamoto A; Oda Y; Adachi T; Oshiro Y; Tamiya S; Tanaka K; Matsuda S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Apr; 14(4):343-9. PubMed ID: 11301351
[TBL] [Abstract][Full Text] [Related]
50. Morphological typing of chondrosarcoma: a study of 94 cases.
Welkerling H; Dreyer T; Delling G
Virchows Arch A Pathol Anat Histopathol; 1991; 418(5):419-25. PubMed ID: 2035255
[TBL] [Abstract][Full Text] [Related]
51. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.
Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC
Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322
[TBL] [Abstract][Full Text] [Related]
52. Chondroid chordomas and low-grade chondrosarcomas of the craniospinal axis. An immunohistochemical analysis of 17 cases.
Wojno KJ; Hruban RH; Garin-Chesa P; Huvos AG
Am J Surg Pathol; 1992 Dec; 16(12):1144-52. PubMed ID: 1463093
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic imaging of malignant cartilage tumors.
Masciocchi C; Sparvoli L; Barile A
Eur J Radiol; 1998 May; 27 Suppl 1():S86-90. PubMed ID: 9652507
[TBL] [Abstract][Full Text] [Related]
54. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
55. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
Masi L; Malentacchi C; Campanacci D; Franchi A
Virchows Arch; 2002 May; 440(5):491-7. PubMed ID: 12021923
[TBL] [Abstract][Full Text] [Related]
56. De-differentiated chondrosarcoma is not a 'de-differentiated' chondrosarcoma.
Aigner T; Dertinger S; Neureiter D; Kirchner T
Histopathology; 1998 Jul; 33(1):11-9. PubMed ID: 9726043
[TBL] [Abstract][Full Text] [Related]
57. Dedifferentiated chondrosarcoma of bone with prominent rhabdoid component.
Stemm M; Beck C; Mannem R; Neilson J; Klein MJ
Ann Diagn Pathol; 2017 Jun; 28():7-11. PubMed ID: 28648942
[TBL] [Abstract][Full Text] [Related]
58. Comparative analysis of miRNA expression in dedifferentiated and well-differentiated components of dedifferentiated chondrosarcoma.
Karras FS; Schreier J; Körber-Ferl K; Ullmann SR; Franke S; Roessner A; Jechorek D
Pathol Res Pract; 2023 Apr; 244():154414. PubMed ID: 36963273
[TBL] [Abstract][Full Text] [Related]
59. Histogenesis of clear cell chondrosarcoma. An immunohistochemical study with osteonectin, a non-collagenous structure protein.
Bosse A; Ueda Y; Wuisman P; Jones DB; Vollmer E; Roessner A
J Cancer Res Clin Oncol; 1991; 117(1):43-9. PubMed ID: 1997469
[TBL] [Abstract][Full Text] [Related]
60. Chondrosarcoma is not characterized by detectable telomerase activity.
Bovée JV; van Den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2001 Mar; 193(3):354-60. PubMed ID: 11241416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
